New York, USA – November 6, 2020 – Recent research has introduced the great potential of T-cell redirecting therapies with gene-engineered CAR T-cells and T-cell engaging bispecific antibodies (bsAbs). However, data solutions require further development to predict response and survival to multiple regimens, and the research of tumorigenesis and drug development should also be accelerated.
To help better understand the novel immunotherapies and the combined methods, Creative Biolabs has invited Dr. Bruno Paiva from Clinica Universidad de Navarra (CUN) and Centro de Investigaciones Medicas Aplicadas (CIMA), Pamplona, Spain to give a presentation during a live webinar, the topic of which is New Ways of Evaluating the Tumor Immune Microenvironment: From Bench to Bedside.
• Recognizing the “friend or foe” relationship between (blood) cancer and immunity
• Leveraging on the immunotherapies for malignant and nonmalignant (hematological) tumors
• Need for next-generation immune monitoring
The webinar will begin at 11:00 AM on November 18th, 2020 (EST) and the free registration has already started. Creative Biolabs, together with Dr. Bruno Paiva, gives warm welcomes to all participants and will be delighted to answer any related questions during the webinar.
With the advancing technologies and platforms, research on various kinds of antibodies has reached outstanding clinical results. To develop bsAbs for treating various diseases, it is of great importance to perform comprehensive bsAb analysis to ensure quality and function. Empowered by a team of experienced experts and cutting-edge platforms, Creative Biolabs provides full coverage of bsAb analysis services, including biochemistry characterization, functional analysis, stability analysis, Pharmacokinetic and Pharmacodynamic (PK/PD) analysis, and preclinical research.
“BsAb PK/PD analysis serves as an important component of the drug discovery and development process since antibody drugs display much more complex PK/PD properties than those common small-molecule drugs,” introduced by a senior scientist at Creative Biolabs. “We can design custom pharmacokinetic studies and accomplish pharmacokinetic calculations. Our high-quality PK/PD analysis services will contribute to the success of your projects.”
More information about Creative Biolabs’ analysis services and products as well as the upcoming webinar can be reached on https://www.creative-biolabs.com/bsab.
About Creative Biolabs
Creative Biolabs was established in 2004 by scientists who are dedicated to conquering cancer. Over the past 15 years, Creative Biolabs has grown into a recognized world leader in antibody discovery, engineering, production, and analysis. Standing on the shoulder of a giant, the bispecific antibody (bsAb) team has a collective of experienced scientists committed to providing high-quality services to customers all over the world. With the cutting-edge platforms and methods, a comprehensive list of BsAb products is also available to customers in academia and industry fields.